Frovatriptan



Frovatriptan
Systematic (IUPAC) name
6-methylamino-6,7,8,9-tetrahydro-
5H-carbazole-3-carboxamide
Identifiers
CAS number 158930-17-7
ATC code N02CC07
PubChem 5284561
DrugBank APRD00270
Chemical data
O 
mol
Pharmacokinetic data
Bioavailability 20-30%
Metabolism Hepatic
Half life 26 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

C: (USA)
B3: (AUS)

Legal status

Prescription only

Routes Oral

Frovatriptan (trade name Frova) is a Menarini in Europe.[1]

Pharmacology

Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

US licensing

Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006,[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).

v • d • e
Antimigraine preparations (Clonidine • Iprazochrome • Dimetotiazine • Oxetorone
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Frovatriptan". A list of authors is available in Wikipedia.